1.	Phase IV Study of Amifostine for Chemotherapy Induced Peripheral Neuropathy in Patients with Cancer (Summary Last Modified 04/2000) Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RNSMC-AM9702, ALZA-RNSMC-AM9702, NCI-V98-1390, NCT00003252
2.	Phase II/III Randomized Study of Amifostine Followed By Protracted Fractionated Radiotherapy in Patients With Inoperable, Unresectable, or Postoperatively Recurrent Rectal Adenocarcinoma (Summary Last Modified 11/2001) Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Completed Age: 18 to physiologic 74 Sponsor: NCI Protocol IDs: UPCC-00-A-0465, NCI-T87-0232
3.	Phase I Pilot/Phase III Randomized Study of CDDP and Combined External-Beam/Intracavitary Radiotherapy with vs without WR-2721 in Patients with Stages IIA-IVA and Selected Stage IB Carcinoma of the Uterine Cervix Phase: Phase III, Phase I Type: Supportive care, Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: AECM-8908198, NCI-V92-0084
4.	Phase III Randomized Study of Radiotherapy with vs without Amifostine for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 04/98) Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: USB-WR-38, NCI-V96-1083
5.	Phase III Randomized Study of Amifostine in Reducing Cisplatin Induced Ototoxicity in Cancer Patients Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCMC-971163, ALZA-UCMC-971163, NCI-V97-1330
6.	Phase III Randomized Study of Amifostine Mucosal Protection in Patients With Favorable Performance Inoperable Stage II, IIIA, or IIIB Non-Small Cell Lung Cancer Receiving Sequential Induction and Concurrent Hyperfractioned Radiotherapy With Paclitaxel and Carboplatin Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-9801, NCT00003313, RTOG-98-01
7.	Phase III Randomized Study of Pentoxifylline, Ciprofloxacin, and Dexamethasone Versus Amifostine in Patients with Myelodysplastic Syndromes (Summary Last Modified 08/1998) Phase: Phase III Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BOSTON-VAMC-523, ALZA-97-047-ii, NCI-V98-1422
8.	Phase III Randomized Study of Amifostine Chemoprotection in Patients With Ovarian Epithelial Cancer Receiving Chemotherapy Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NU-97CC4, NCI-G99-1633, NCT00004166
9.	Phase III Randomized Comparison of CACP vs CACP plus WR-2721 in Patients with Disseminated Malignant Melanoma Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: EST-1686
10.	Phase III Study of High-Dose CTX plus GM-CSF with vs without WR-2721 Chemoprotection in Patients with Advanced Malignancies Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9160, CALGB-9160
11.	Phase III Randomized Study of Amifostine Versus No Treatment For Platinum-Induced Peripheral Neuropathy in Patients With Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0192, NCT00058071
12.	Phase I/II Study of High Dose Paclitaxel, Cyclophosphamide, and Cisplatin Conditioning, Amifostine Cytoprotection, Purified Autologous Hematopoietic Progenitor/Stem Cell Transplantation, and Posttransplant Immunomodulation with an Anti-Idiotype Vaccine in Patients with Metastatic Breast Cancer (Summary Last Modified 09/98) Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: UKMC-96BMT59, ALZA-UKMC-96BMT59, NCI-V97-1332
13.	Phase I/II Study of Amifostine in Patients with Myelodysplasia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-97076, ALZA-97-013-ii, NCI-G97-1338
14.	Phase I/II Study of Carboplatin Following Amifostine to Augment High Dose Cyclophosphamide with Autologous Peripheral Blood Cell Support for Refractory or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (Summary Last Modified 05/2000) Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 65 and under Sponsor: Pharmaceutical / Industry Protocol IDs: UCCRC-8433, ALZA-97-005-ii, NCI-V97-1357, NCT00003136
15.	Phase I/II Study of Amifostine in Ameliorating Chronic Toxicity of Fludarabine Monophosphate Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UARIZ-HSC-97116, ALZA-UARIZ-HSC-97116, NCI-V98-1371
16.	Phase I/II Study of Paclitaxel, Amifostine, and Accelerated Hyperfractionated Radiotherapy in Patients With Stage III or IV Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MGH-M7-20, ALZA-97-024-ii, NCI-V98-1384, NCT00003193
17.	Phase I/II Study of Amifostine as a Protective Agent for Irinotecan Toxicities in Patients with Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-HSPC-970304601B, ALZA-UCLA-HSPC-970304601B, NCI-G98-1390, NCT00003225
18.	Phase I/II Study of Amifostine in Combination with Cisplatin, Paclitaxel, and Radiation Therapy in Patients with Locally Advanced, Unresectable Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UIC-H-97-783, ALZA-UIC-H-97-783, NCI-V98-1389, NCT00003251
19.	Phase I/II Study of Amifostine plus Topotecan in Patients with Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UARIZ-HSC-97148, ALZA-97-017-ii, NCI-V98-1454, NCT00003415
20.	Phase I/II Study of High Dose Melphalan with Autologous Peripheral Blood Stem Cell Support and Amifostine Cytoprotection in Cancer Patients Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 14 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: UKMC-97BMT72, ALZA-UKMC-97BMT72, NCI-V98-1455, NCT00003425
21.	Phase I/II Study of Hyperfractionated Radiation Therapy and Fluorouracil, Cisplatin, and Paclitaxel With Amifostine Chemoradioprotection in Stage III or IV Unresectable Head and Neck Carcinoma Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SCCC-97098, ALZA-97-052-ii, BHM-98-32, NCI-V98-1474, NCT00003582
22.	Phase I/II Study of Docetaxel, High Dose Cisplatin, and Amifostine in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: WCCC-CO-9653, NCI-G00-1668, NCT00004264
23.	Phase II Study of Topotecan and Paclitaxel Before and After High-Dose Thoracic Radiotherapy With Concurrent Cisplatin, Etoposide, and Amifostine in Patients With Limited Stage Small Cell Lung Cancer (Phase I closed to accrual as of 5/29/2004) Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N9923, N9923, NCT00006012
24.	Phase I/II Study of External Beam Radiotherapy, Intracavitary Brachytherapy, and Cisplatin With or Without Amifostine in Patients With Para-Aortic or High Common Iliac Lymph Node-Positive Carcinoma of the Uterine Cervix Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-C-0116, RTOG-0116, NCT00012012
25.	Phase I/II Evaluation of WR-2721 as a Protector Against CACP-Induced Nephrotoxicity Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MDA-DT-8122, NCI-W81-0703